ArticleHealth economics review2026
Productivity costs of type 2 diabetes with or without co-occurring substance use disorder and depression.
Article in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression and substance use disorders are common causes of disability and often co-occur with type 2 diabetes (T2D). This study aimed to assess productivity costs using both human capital (HC) and friction cost (FC) methods and to examine how these costs change with age among people with T2D, with or without co-occurring substance use disorders and depression.
methodsThe FinDM database was used to identify individuals of working age (age 30 or older) with T2D (N = 377,560) and comorbidities between 1998 and 2017. Individual-level productivity costs were estimated using both the FC and HC methods. The progression of annual mean costs and the associations of T2D and the comorbidities with these costs were analysed using piecewise linear generalized estimating equation models.
resultsPeople with T2D and the comorbidities incurred over sevenfold annual productivity costs at age 45 compared with those without these comorbidities (€6,320 vs €856). Mean costs showed a notable annual increase (€180 per year) after age 50 years and peaked near the statutory retirement age. At the peak, the annual mean FC and HC estimates were €5,000 and €20,000, respectively. Diagnoses of T2D, substance use disorder, and depression were associated with additional annual FC costs of €53, €195, and €202, respectively.
conclusionsCo-occurring substance use disorders and depression are associated with higher productivity costs among people with T2D, with substantially stronger associations than those observed for T2D alone. These findings highlight the importance of identifying high-risk individuals and allocating health care resources toward integrated, holistic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.